Abstract
This report analyzes the hot global market for biomarkers and related assays
or tests used in drug R&D. The study reviews this dynamic market by looking
at drug research and development spending trends, M&As, alliances, major
diseases, applications, tools, technologies, products and services. This
report suggests the future direction of the market for biomarkers and related
' -omic' or pharmacogenomic (PGx) assays or tests used in the next-generation
of drug R&D. This study sizes the world market and growth rate of biomarkers
and assays for drug R&D spending to 2012.
Drug and biopharmaceutical developers face numerous challenges that are being
helped with emerging business and technical strategies or approaches that
utilize biomarkers to improve their chances of success. This business area is
set for strong continued growth as biomarkers and assays in drug R&D enable
new opportunities. This report estimates that this potential multi-billion
dollar market will grow at strong double-digit rates over the five-year study
period.
The study discusses ongoing regional government initiatives that are fostering
worldwide development in biomarkers and personalized medicine opportunities.
With the current group of more than 20-marketed personalized medicines and
companion tests as a model, government drug regulators have already begun to
change the labels of selected marketed drugs to use specific companion tests
to predict patient drug response. Drug regulators are asking that drug makers
use certain kidney safety biomarker assays in drug R&D. Their goal is to
streamline commercializing new, safer, more effective drugs and co-developed
companion predictive tests by integrating biomarkers and related
pharmacogenomic (PGx), protein, imaging or other tests into the drug R&D
critical path. The study discusses how clinical trials are undergoing
important changes that integrate biomarkers and assays into the drug R&D
process to provide more meaningful information in order for drug makers to
make better product development decisions.
This study uses more than 51 figures and tables to illustrate its useful
findings. The report offers detailed information including data tables about
strategic technologies, M&As, alliances and so on. Thirty-four selected
companies are profiled with details such as business overview, contacts,
financial details and product information. This fully searchable PDF report
helps busy readers save time. This report uses hyperlinks to help readers jump
to Table of Content items or to text-linked Internet sites.
This must-have report would benefit people with job titles including CEO, VPs,
Director of Business Development, Research Directors, Entrepreneurs, Venture
Capitalists, Investment Planners, Research Scientists, Consultants or Industry
Analysts.
About Takeda Pacific
Consultants at Takeda Pacific developed this report. The company provides
business consulting that focuses on facilitating business development and
market research projects. The business projects may involve European, Japanese
and North American Life Science companies. Since it' s founding in late 1992,
TP has reviewed or analyzed over 5,200 Life Science and Technology firms for
its clients.
Since 1992, Takeda Pacific has produced more than 70 industry reports about
emerging pharma, biotech, med-devices and technology companies and markets.
Takeda Pacific also offers follow-up consulting or custom research consulting
to assist in your business development or benchmarking, market assessment
projects.
| 
View Cart
